Rarely has my “regulatory life” been as intense and as rich in insights and progress as recently. Three brief examples from just last week that also affect you:
1. Automated TD reviews at Notified Bodies
Last week, a representative of a Notified Body attended my workshop “AI Power for the Development and Approval of Medical Devices,” where I demonstrated how alarmingly effective automated reviews of technical documentation (TD) have become.
He announced that his Notified Body would also pursue this path. In one of the upcoming podcast episodes, he will speak about it. So keep following the Medical Device Briefings.
But the consequences are already clear: full reviews of technical documentation will become the new standard. For AI, it makes little difference whether it reviews individual documents, individual files, or an entire TD.
2. My experiment: tailor-made software (n = 1) in just a few weeks
I was somewhat overwhelmed by the feedback on my planned experiment, which I announced here last week. There were many words of encouragement and well wishes. One comment, in particular, made me pause:
“I’m curious and secretly hoping for failure. Not out of malice, but out of fear for the future. 😀”
I understand - and share - that fear.
Consequence: If we would rather not become victims of AI, we must seize the unique opportunities it offers. In Johner’s AI Lab: The Expedition, I show my path.
If you would like to use it as a blueprint, you’ll need to register quickly - we have only a few places left.
3. Increasing development speed
Another question raised during the workshop was how to accelerate development. The obvious implication: with AI.
I have given this considerable thought.
My answer is neither comfortable nor related to AI - as you will see in today’s Executive Corner.
Regulatory Updates
a. UK
The UK’s MHRA has launched a consultation on whether the CE marking should continue to be accepted indefinitely in the United Kingdom.
Common sense - or a political U-turn?
After Brexit, there was much talk about introducing distinct British regulations and moving away from EU-style bureaucracy. Yet no truly exemplary regulatory framework has emerged.
With the UKCA marking, the United Kingdom preserves its regulatory sovereignty - without reinventing the game for companies that wish to continue selling CE-marked products. This leaves room for innovative regulatory approaches - which we are all hoping for.
b. Team-NB on IVD reagents
In a new position paper, Team-NB specifies the evidence expectations for combined use of IVD reagents with other products.
The paper distinguishes between “closed systems” (clearly defined combinations with specified products) and “open systems.” In the latter case, manufacturers must define permissible combinations via critical product specifications or characteristics - without naming a specific product.
Overall, there is nothing groundbreaking, and it aligns with the Johner Institute’s understanding. We find the following particularly helpful:
- The emphasis on a risk-based approach (ISO 14971)
- Performance evidence for each combination or justified transferability
- Clear IFU/labeling statements
- The clarification that when RUO or General Laboratory Use products are part of the workflow, the responsibility for evidence lies with the IVD manufacturer (including a PMS focus on combination workflows)
My colleague Dr. Sophie Bartsch has updated our technical articles accordingly (see below).
c. AI Implementation Act
The German Cabinet has adopted the draft AI Implementation Act.
Its key content includes the designation of:
- the supervisory authorities (including BaFin),
- the component authorities for Annex I, Section A products (including medical devices and IVD): the same as before, i.e., ZLG,
- the conformity assessment bodies: unchanged (good news!),
- the composition of the “AI Market Surveillance Chamber” (including the Federal Network Agency, which is also assigned numerous additional responsibilities under the AI Act),
- the powers of the market surveillance authorities.
According to the draft, the administrative burden for public authorities will increase by approximately € 49 million per year. No additional burden is expected for citizens or businesses, as this was already created by the AI Act itself.